CD22 and B-cell acute lymphoblastic leukemia: A phase I trial of CAR-T cells with CD19 and CD22 in young patients with relapsed or refractory B-cell acute lymphoblastic leukemia demonstrated controlled toxicity, with 5 out of 12 patients showing complete remission (57).